COPD Exacerbation Follow Up

Study on AI-Enabled Workflow Tool for Chronic Obstructive Pulmonary Disease Exacerbation

Recruiting
40 years or above
All
Phase N/A
485 participants needed
2 Locations

Study Overview

The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.

Study Details

Time perspective: This study will collect data prospectively for the Experimental cohort and retrospectively for the Control cohort. There is also an Exploratory cohort which will collect retrospective and prospective data.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: COPD (Chronic Obstructive Pulmonary Disease)
  • Age: 40 years or above
  • Gender: All

Inclusion Criteria:

  • Patients aged 40 years or older at the time of arrival to the emergency department.
  • Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation.
  • A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics.
  • A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for >24 hours in emergency department/urgent care facility or resulting in death.
  • Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers.

Exclusion Criteria:

  • Patients on bronchodilator inhaler monotherapy.
  • Patients leaving against medical advice or expiring during hospitalization.
  • Patients with tracheostomy.
  • Patients with advanced cancer.
  • Patients who have received a lung transplant.
  • Discharge to hospice care.
  • Transfer to another hospital.

This study investigates the impact of using an AI-enabled clinical workflow tool on follow-up care and outcomes for people with COPD after they have an acute exacerbation.

The study focuses on understanding how this tool affects the care provided by respiratory specialists and the overall health results of patients after they experience worsening symptoms of COPD.

  • Who can participate: Adults aged 40 years or older with a clinical diagnosis of COPD who visit the emergency department for a moderate or severe exacerbation can participate. Participants must be using dual or triple long-acting bronchodilator inhalers.
  • Study details: Participants will interact with the AI tool during follow-up visits to monitor its impact on their care. The study will collect data on treatment adjustments, healthcare utilization, and patient-reported outcomes to compare different groups.
Updated on 26 Mar 2026. Study ID: NCT07118306

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language